Knee osteoarthritis with obesity — evidence across compounds
Every compound the Institute assesses in knee osteoarthritis with obesity, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in knee osteoarthritis with obesity, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| AOD-9604Growth-hormone C-terminal fragment analogue | A small trial in knee osteoarthritis reported no significant benefit on the primary endpoint | negative result | Low | 1 |
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | WOMAC pain score improvement exceeding placebo at 68 weeks | reported difference of approximately 8 points on a 0–100 scale | Low | 1 |
| BPC-157Synthetic pentadecapeptide derived from a gastric juice… | No randomised controlled human trial identified | — | Very low | 0 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
No evidence synthesis addresses this indication.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522 · PMID 11713213
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.